ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Siqing Fu
Matched on ORCID iD 0000-0002-1933-0419; OpenAlex author ID A5045197829. Sources: ClinicalTrials.gov.
Their work
- Papers
- 1
- Trials
- 3 (principal investigator on 3)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2017: 1 paper · 2018: none · 2019: 1 trial · 2020: none · 2021: none · 2022: 1 trial · 2023: none · 2024: 1 trial
Papers 1
Trials 3
- Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epith… Principal investigator NCT06576037↗
- Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors Principal investigator NCT05431582↗
- A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors Principal investigator NCT03784677↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Funda Meric-Bernstam · 1 shared paper, 2017 · strength 0.05
- Milind M. Javle · 1 shared paper, 2017 · strength 0.05
- Sarina Anne Piha-Paul · 1 shared paper, 2017 · strength 0.05
- Jennifer Brooke Goldstein · 1 shared paper, 2017 · strength 0.05
- Chad Z. Tang · 1 shared paper, 2017 · strength 0.05
- Robert A. Wolff · 1 shared paper, 2017 · strength 0.05
- Kenneth R. Hess · 1 shared paper, 2017 · strength 0.05
- Apostolia Maria Tsimberidou · 1 shared paper, 2017 · strength 0.05
- Gauri Rajani Varadhachary · 1 shared paper, 2017 · strength 0.05
- Vivek Subbiah · 1 shared paper, 2017 · strength 0.05
- David R. Fogelman · 1 shared paper, 2017 · strength 0.05
- David S. Hong · 1 shared paper, 2017 · strength 0.05
- Aung Naing · 1 shared paper, 2017 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.